Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Reads0
Chats0
TLDR
In this article, the authors reviewed data on immunoproteasome function and inhibition in hematopoietic cells and hematologic cancers and showed promising preliminary results in pre-clinical studies and one inhibitor is currently being investigated in clinical trials for the treatment of multiple myeloma.Abstract:
The ubiquitin-proteasome system (UPS) is a central part of protein homeostasis, degrading not only misfolded or oxidized proteins but also proteins with essential functions. The fact that a healthy hematopoietic system relies on the regulation of protein homeostasis and that alterations in the UPS can lead to malignant transformation makes the UPS an attractive therapeutic target for the treatment of hematologic malignancies. Herein, inhibitors of the proteasome, the last and most important component of the UPS enzymatic cascade, have been approved for the treatment of these malignancies. However, their use has been associated with side effects, drug resistance, and relapse. Inhibitors of the immunoproteasome, a proteasomal variant constitutively expressed in the cells of hematopoietic origin, could potentially overcome the encountered problems of non-selective proteasome inhibition. Immunoproteasome inhibitors have demonstrated their efficacy and safety against inflammatory and autoimmune diseases, even though their development for the treatment of hematologic malignancies is still in the early phases. Various immunoproteasome inhibitors have shown promising preliminary results in pre-clinical studies, and one inhibitor is currently being investigated in clinical trials for the treatment of multiple myeloma. Here, we will review data on immunoproteasome function and inhibition in hematopoietic cells and hematologic cancers.read more
Citations
More filters
Journal ArticleDOI
Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation.
TL;DR: In this paper, a review summarizes the function of the main proinflammatory cytokines and acute phase response proteins and their signaling pathways in inflammation-induced muscle atrophy with a focus on UPS-mediated protein degradation in muscle during sepsis.
Journal ArticleDOI
On the Role of the Immunoproteasome in Protein Homeostasis.
Michael Basler,Marcus Groettrup +1 more
TL;DR: The immunoproteasome is a special type of proteasome which is inducible under inflammatory conditions and constitutively expressed in hematopoietic cells.
Journal ArticleDOI
At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention
Grazia R. Tundo,Diego Sbardella,Francesco Oddone,Anna Kudriaeva,Pedro Miguel Lacal,Alexey A. Belogurov,Grazia Graziani,Stefano Marini +7 more
TL;DR: In this paper, the role of immunoproteasome in antigen processing and the therapeutic implication of its modulation is investigated. But the potential crosstalk between proteasome modulators and immune checkpoint inhibitors is not explored.
Journal ArticleDOI
Proteasome dysfunction disrupts adipogenesis and induces inflammation via ATF3
TL;DR: In this article , the authors investigated the impact of two proteasome subunits implicated in PRAAS, Psmb4 and Psmb8, on differentiation, function and proteostasis of brown adipocytes.
Journal ArticleDOI
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Silvia D’Amico,Patrizia Tempora,Ombretta Melaiu,Valeria Lucarini,Loredana Cifaldi,Franco Locatelli,Doriana Fruci +6 more
TL;DR: An overview of the key elements of the APP machinery that can be exploited to enhance tumor immunogenicity and increase the efficacy of ICI-based immunotherapy is provided.
References
More filters
Journal ArticleDOI
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
Michael Karin,Yinon Ben-Neriah +1 more
TL;DR: Recent progress has been made in understanding the details of the signaling pathways that regulate NF-kappaB activity, particularly those responding to the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1.
Journal ArticleDOI
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.
Christina Fitzmaurice,Christina Fitzmaurice,Christina Fitzmaurice,Tomi Akinyemiju,Faris Lami,Tahiya Alam,Reza Alizadeh-Navaei,Christine Allen,Ubai Alsharif,Nelson Alvis-Guzman,Erfan Amini,Benjamin O. Anderson,Olatunde Aremu,Al Artaman,Solomon Weldegebreal Asgedom,Reza Assadi,Tesfay Mehari Atey,Leticia Avila-Burgos,Ashish Awasthi,Huda Omer Ba Saleem,Aleksandra Barac,James R. Bennett,Isabela M. Benseñor,Nickhill Bhakta,Hermann Brenner,Lucero Cahuana-Hurtado,Carlos A Castañeda-Orjuela,Ferrán Catalá-López,Ferrán Catalá-López,Jee-Young Jasmine Choi,Jee-Young Jasmine Choi,Devasahayam J. Christopher,Sheng-Chia Chung,Maria Paula Curado,Lalit Dandona,Lalit Dandona,Rakhi Dandona,Rakhi Dandona,José Neves,Subhojit Dey,Samath D Dharmaratne,David Teye Doku,David Teye Doku,Tim Driscoll,Manisha Dubey,Hedyeh Ebrahimi,Dumessa Edessa,Ziad El-Khatib,Ziad El-Khatib,Aman Yesuf Endries,Florian Fischer,Lisa M. Force,Kyle J Foreman,Kyle J Foreman,Solomon Weldemariam Gebrehiwot,Sameer Vali Gopalani,Giuseppe Grosso,Rahul Gupta,Bishal Gyawali,Randah R. Hamadeh,Samer Hamidi,James D. Harvey,Hamid Yimam Hassen,Roderick J. Hay,Simon I. Hay,Simon I. Hay,Behzad Heibati,Molla Kahssay Hiluf,Nobuyuki Horita,H. Dean Hosgood,Olayinka Stephen Ilesanmi,Kaire Innos,Farhad Islami,Mihajlo Jakovljevic,Mihajlo Jakovljevic,Sarah Charlotte Johnson,Jost B. Jonas,Amir Kasaeian,Tesfaye Dessale Kassa,Yousef Khader,Ejaz Ahmad Khan,Gulfaraz Khan,Young-Ho Khang,Young-Ho Khang,Mohammad Hossein Khosravi,Mohammad Hossein Khosravi,Jagdish Khubchandani,Jacek A. Kopec,G Anil Kumar,Michael Kutz,Deepesh Lad,Alessandra Lafranconi,Qing Lan,Yirga Legesse,James Leigh,Shai Linn,Raimundas Lunevicius,Raimundas Lunevicius,Azeem Majeed,Reza Malekzadeh,Deborah Carvalho Malta,Lorenzo G. Mantovani,Brian J. McMahon,Toni Meier,Yohannes Adama Melaku,Yohannes Adama Melaku,Mulugeta Melku,Peter Memiah,Walter Mendoza,Tuomo J. Meretoja,Haftay Berhane Mezgebe,Ted R. Miller,Ted R. Miller,Shafiu Mohammed,Shafiu Mohammed,Ali H. Mokdad,Mahmood Moosazadeh,Paula Moraga,Seyyed Meysam Mousavi,Vinay Nangia,Cuong Tat Nguyen,Vuong Minh Nong,Felix Akpojene Ogbo,Andrew T Olagunju,Andrew T Olagunju,Andrew T Olagunju,Padukudru Anand Mahesh,Eun-Kee Park,Tejas Patel,David M. Pereira,Farhad Pishgar,Maarten J. Postma,Maarten J. Postma,Farshad Pourmalek,Mostafa Qorbani,Anwar Rafay,Salman Rawaf,David Laith Rawaf,David Laith Rawaf,Gholamreza Roshandel,Gholamreza Roshandel,Saeid Safiri,Hamideh Salimzadeh,Juan Sanabria,Juan Sanabria,Milena M Santric Milicevic,Benn Sartorius,Benn Sartorius,Maheswar Satpathy,Sadaf G. Sepanlou,Katya Anne Shackelford,Masood Ali Shaikh,Mahdi Sharif-Alhoseini,Jun She,Min-Jeong Shin,Ivy Shiue,Ivy Shiue,Mark G. Shrime,Abiy Hiruye Sinke,Mekonnen Sisay,Amber Sligar,Mu'awiyyah Babale Sufiyan,Bryan L. Sykes,Rafael Tabarés-Seisdedos,Gizachew Assefa Tessema,Gizachew Assefa Tessema,Roman Topor-Madry,Roman Topor-Madry,Tung Thanh Tran,Bach Xuan Tran,Bach Xuan Tran,Kingsley N. Ukwaja,Vasiliy Victorovich Vlassov,Stein Emil Vollset,Elisabete Weiderpass,Hywel C Williams,Nigus Bililign Yimer,Naohiro Yonemoto,Mustafa Z. Younis,Christopher J L Murray,Mohsen Naghavi +180 more
TL;DR: In this paper, the authors assess the burden of 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus, and evaluate cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods.
Journal ArticleDOI
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
TL;DR: It is clear now that degradation of cellular proteins is a highly complex, temporally controlled, and tightly regulated process that plays major roles in a variety of basic pathways during cell life and death as well as in health and disease.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
Kenneth L. Rock,Colette F. Gramm,Lisa Rothstein,Karen Clark,Ross L. Stein,Lawrence Dick,Daniel Hwang,Alfred L. Goldberg +7 more
TL;DR: Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degradation of protein and ubiquitinated protein substrates by 26S particles.
Related Papers (5)
The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
Yan-Jie Chen,Hao Wu,Xizhong Shen +2 more
Proteasome dysregulation in human cancer: implications for clinical therapies
Yulin Chen,Yanan Zhang,Xing Guo +2 more